ClinicalTrials.gg
Not yet recruitingNCT07945353Updated Nov 18, 2026

Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma

A Phase 2 interventional study of Orelabrutinib and 4 Gy Involved-Site Radiotherapy (ISRT) in MALT Lymphoma, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone — 17 open to participants now, 21 under way, 1 of them phase 3. orelabrutinib · Lymphoma, B-Cell, Marginal Zone.

Planned enrollment
2nd of 21
272 · median 51
Started
2026
with 3 others
Phase 2
17 of 21
13 open now
Primary completion
2031-12
later than 20 of 20 live
Registered
21st of 21
by date
Lead sponsor
2 of 21
Fudan University

Among the 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 20 of the 20 other live ones, and was the 21st registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

17 of the 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, or all of them as a file.
02

Study summary

This is a multicenter, open-label, randomized, controlled phase II study evaluating the efficacy and safety of short-course orelabrutinib induction followed by low-dose involved-site radiotherapy (ISRT) compared with standard-dose ISRT in patients with previously untreated, limited-stage extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).

Read the detailed description

Eligible patients will be randomized in a 1:1 ratio to either the experimental arm or the control arm. Patients in the experimental arm will receive oral orelabrutinib for 12 weeks followed by 4 Gy ISRT (2 Gy × 2 fractions), while patients in the control arm will receive 24 Gy ISRT (2 Gy × 12 fractions).

The primary endpoint is the 2-year progression-free survival (PFS) rate. Key secondary endpoints include the radiotherapy omission rate, 2-year event-free survival (EFS), complete response (CR) rate, objective response rate (ORR), in-field and out-of-field recurrence rates, safety, and quality of life (QoL).

03

Conditions studied

  • MALT Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • confirmed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
  • MALT lymphoma involving, but not limited to, the following sites: orbit, parotid gland, thyroid, Helicobacter pylori (H. pylori)-negative gastric MALT lymphoma, lung, intestine, prostate, and other sites.

For gastric MALT lymphoma, H. pylori negativity must be confirmed by a 13C-urea breath test or gastric mucosal histology. For patients with unknown prior H. pylori status who have previously received H. pylori eradication therapy, serum H. pylori antibody may remain positive. In such cases, at least 1 year must have elapsed since completion of eradication therapy, and repeat gastroscopy and/or breath testing must be negative. Patients with a history of H. pylori infection must have the eradication regimen documented. If t(11;18) testing is available, the result should also be documented for exploratory analysis.

  • Lugano stage I-II disease. Staging will be performed according to the Lugano classification. Limited-stage disease eligible for this study is defined as all known MALT lymphoma lesions being confined to a single organ or paired organs, with or without regional lymph node involvement, and all disease being safely amenable to coverage by limited-field curative-intent involved-site radiotherapy (ISRT).
  • (ECOG) performance status of 0-2.
  • Ability to understand and willingness to voluntarily provide written .
  • Adequate organ function, defined as follows:

    1. Hematologic function: ≥1.0 × 10\^9/L, count ≥50 × 10\^9/L, and ≥80 g/L.
    2. Hepatic function: total ≤1.5 × the (ULN), (ALT) and aspartate aminotransferase (AST) \<3 × ULN, and serum albumin ≥30 g/L.
    3. Renal function: serum creatinine \<1.5 × ULN and ≥50 mL/min, calculated using the standard Cockcroft-Gault formula. For renal impairment caused by tumor compression, creatinine clearance ≥30 mL/min is acceptable.
    4. Coagulation function: unless the participant is receiving anticoagulant therapy and the coagulation parameters ( and APTT) are within the expected range for the anticoagulant treatment, international normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 4 weeks before enrollment, except for diagnostic surgery.
  • Uncontrolled concomitant diseases, including cardiovascular or cerebrovascular disease, coagulation disorders, and severe infectious diseases, including but not limited to:

    1. severe acute or chronic infections requiring systemic treatment;
    2. symptomatic congestive heart failure ( class III-IV);
    3. symptomatic or inadequately controlled arrhythmia;
    4. inadequately controlled arterial hypertension despite standard treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
    5. unstable angina;
    6. active peptic ulcer disease or bleeding disorders.
  • Severe concomitant diseases that may interfere with routine treatment.
  • Known active interstitial pneumonia.
  • Viral hepatitis and other active infections:

    1. Active chronic infection, defined as positive hepatitis B virus (HBV) DNA. Patients with latent or prior HBV infection (defined as positive hepatitis B surface antigen [HBsAg] or total hepatitis B core antibody [HBcAb]) may be enrolled if HBV DNA is undetectable at screening. Such patients must be willing to undergo regular HBV DNA monitoring and receive appropriate antiviral therapy as required by the study.
    2. Patients with positive virus (HCV) antibody may participate only if HCV RNA is negative by polymerase chain reaction (PCR).
    3. Active infection with (HIV) or syphilis.
  • Pregnant or breastfeeding women.
  • Dysphagia or inability to take oral medication on a long-term basis.
  • Patients considered unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib + 4 Gy ISRT

    Participants will receive oral orelabrutinib for 12 weeks, followed by 4 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 2 fractions. Radiotherapy will be initiated within 4 weeks after completion of orelabrutinib. Response will be assessed after treatment, and additional local radiotherapy or salvage treatment may be administered according to the predefined response-based management strategy.

    Drug: Orelabrutinib · Radiation: 4 Gy Involved-Site Radiotherapy (ISRT)

  • Active comparator
    24 Gy ISRT

    Participants will receive 24 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 12 fractions. Radiotherapy will be initiated within 4 weeks after randomization. Patients with inadequate response may receive salvage treatment at the investigator's discretion.

    Radiation: 24 Gy Involved-Site Radiotherapy (ISRT)

Interventions

  • Orelabrutinib 150 mg orally once daily for 12 weeks. Dose interruption and reduction are permitted according to the protocol-defined toxicity management criteria.

  • Radiation4 Gy Involved-Site Radiotherapy (ISRT)

    Involved-site radiotherapy (ISRT) at a total dose of 4 Gy, delivered as 2 Gy in 2 fractions, following the ILROG-recommended technical framework for extranodal lymphoma and ISRT. Radiotherapy is initiated within 4 weeks after completion of orelabrutinib treatment.

  • Radiation24 Gy Involved-Site Radiotherapy (ISRT)

    Involved-site radiotherapy (ISRT) at a total dose of 24 Gy, delivered as 2 Gy in 12 fractions. Radiotherapy is initiated within 4 weeks after randomization.

06

What researchers measure

Primary outcomes

  1. 2-year Progression-Free Survival (PFS) Rate

    Progression-free survival is defined as the time from randomization to the first documented disease progression or death from any cause. Participants without a PFS event at the data cutoff will be censored at the date of the last adequate tumor assessment. Additional 20 Gy radiotherapy administered according to the protocol-defined response-adapted treatment strategy is not considered a PFS event and will not result in censoring.

    Time frame: 2 years after randomization

Secondary outcomes

  1. Radiotherapy Omission Rate

    The proportion of participants in the experimental arm who receive no additional 20 Gy radiotherapy or other local salvage radiotherapy from randomization through 24 months. The denominator is the intent-to-treat population in the experimental arm, excluding participants who do not receive the planned 4 Gy radiotherapy. Participants who are lost to follow-up, receive radiotherapy outside the protocol, or receive other anti-lymphoma treatment are included in the denominator.

    Time frame: From randomization through 24 months

  2. 2-year Event-Free Survival (EFS) Rate

    Event-free survival is defined as the time from randomization to the occurrence of any event, including discontinuation of orelabrutinib because of toxicity, failure to complete 4 Gy radiotherapy, death, disease relapse, disease progression, initiation of a new anti-lymphoma treatment, or additional radiotherapy.

    Time frame: 2 years after randomization

  3. Objective Response Rate (ORR)

    The proportion of participants who achieve a complete response or partial response according to the study-defined response assessment criteria based on the Lugano 2014 framework, with site-specific adaptations for extranodal MALT lymphoma.

    Time frame: Throughout the treatment period, up to 2 years

  4. Complete Response (CR) Rate

    The proportion of participants who achieve a complete response according to the study-defined response assessment criteria based on the Lugano 2014 framework, with site-specific adaptations for extranodal MALT lymphoma.

    Time frame: Throughout the treatment period, up to 2 years

  5. Local Recurrence Rate at the Irradiated Site

    The proportion of participants who develop disease recurrence at the previously irradiated site during follow-up.

    Time frame: From randomization through 24 months

  6. Incidence of Adverse Events

    Safety will be assessed by the incidence and severity of adverse events in participants who receive at least one dose of study treatment or at least one radiotherapy treatment. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0.

    Time frame: up to 2 years

  7. Quality of life questionnaire(EORTC QLQ-C30)

    evaluate patients' quality of life by questionnaire using EORTC QLQ-C30.There are a total of 30 entries. Among them, items 29 and 30 are divided into seven levels, ranging from 1 to 7 points based on their answer options; The other items are divided into four levels: none, a little, many to many, and are rated directly on a scale of 1 to 4.

    Time frame: Up to 2 years

07

Study locations

1 site
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    • Rong Tao, MD · Contactrtao@shca.org.cn · 8621-64175590
    • · Contact8621-64175590
    • Rong Tao, MD&PhD · Principal investigator
    • Yizhen Liu, MD&PhD · Principal investigator
    • Xuejun Ma, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2031, 61 months later.

Of 97 non-industry phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 61 months is below that.

Counting every sponsor, half of 113 studies reached it within 69 months; a quarter within 38 and three quarters within 110.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Nov 18, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Jun 30, 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07945353
Lead sponsor
Fudan University
Responsible party
Rong Tao (Clinical Professor, Fudan University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 18, 2026 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Rong Tao
Contact
rtao@shca.org.cn
02164175590
Yizhen Liu
Contact
aliuyz@126.com
Rong Tao, MD & PhD
study chair · Fudan University
Yizhen Liu, MD & PhD
principal investigator · Fudan University
Xuejun Ma, MD
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion